IN2012DN00763A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00763A
IN2012DN00763A IN763DEN2012A IN2012DN00763A IN 2012DN00763 A IN2012DN00763 A IN 2012DN00763A IN 763DEN2012 A IN763DEN2012 A IN 763DEN2012A IN 2012DN00763 A IN2012DN00763 A IN 2012DN00763A
Authority
IN
India
Prior art keywords
diseases
hdl
prophylaxis
atherosclerosis
medicaments
Prior art date
Application number
Other languages
English (en)
Inventor
Stephan Roever
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN00763A publication Critical patent/IN2012DN00763A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN763DEN2012 2009-09-11 2010-09-08 IN2012DN00763A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (1)

Publication Number Publication Date
IN2012DN00763A true IN2012DN00763A (fi) 2015-06-26

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
IN763DEN2012 IN2012DN00763A (fi) 2009-09-11 2010-09-08

Country Status (35)

Country Link
US (1) US8227491B2 (fi)
EP (1) EP2475645B1 (fi)
JP (1) JP5604520B2 (fi)
KR (1) KR101382871B1 (fi)
CN (1) CN102639506B (fi)
AR (2) AR078352A1 (fi)
AU (1) AU2010294277B2 (fi)
BR (1) BR112012005511B8 (fi)
CA (1) CA2771493C (fi)
CL (1) CL2012000611A1 (fi)
CO (1) CO6491033A2 (fi)
CR (1) CR20120089A (fi)
CY (1) CY1114377T1 (fi)
DK (1) DK2475645T3 (fi)
EC (1) ECSP12011723A (fi)
ES (1) ES2423821T3 (fi)
HK (1) HK1172021A1 (fi)
HR (1) HRP20130869T1 (fi)
IL (1) IL217920A (fi)
IN (1) IN2012DN00763A (fi)
MA (1) MA33563B1 (fi)
MX (1) MX2012002254A (fi)
MY (1) MY161103A (fi)
NZ (1) NZ597514A (fi)
PE (1) PE20120863A1 (fi)
PL (1) PL2475645T3 (fi)
PT (1) PT2475645E (fi)
RS (1) RS52987B (fi)
RU (1) RU2541475C2 (fi)
SG (1) SG179035A1 (fi)
SI (1) SI2475645T1 (fi)
TW (1) TWI412363B (fi)
UA (1) UA107088C2 (fi)
WO (1) WO2011029827A1 (fi)
ZA (1) ZA201201599B (fi)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) * 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
DE602006007563D1 (de) * 2005-04-06 2009-08-13 Hoffmann La Roche Agonisten
EP2450350A1 (en) 2006-10-04 2012-05-09 F. Hoffmann-La Roche AG 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents

Also Published As

Publication number Publication date
CR20120089A (es) 2012-03-22
PL2475645T3 (pl) 2013-12-31
PE20120863A1 (es) 2012-07-23
CA2771493C (en) 2017-08-29
EP2475645A1 (en) 2012-07-18
BR112012005511B1 (pt) 2021-03-02
AU2010294277B2 (en) 2015-07-09
IL217920A0 (en) 2012-03-29
ZA201201599B (en) 2012-11-28
RU2541475C2 (ru) 2015-02-20
CO6491033A2 (es) 2012-07-31
RS52987B (en) 2014-02-28
KR20120048040A (ko) 2012-05-14
ES2423821T3 (es) 2013-09-24
CA2771493A1 (en) 2011-03-17
CN102639506A (zh) 2012-08-15
BR112012005511A2 (pt) 2016-04-19
AU2010294277A1 (en) 2012-02-09
MY161103A (en) 2017-04-14
AR114032A2 (es) 2020-07-15
RU2012113924A (ru) 2013-10-20
SI2475645T1 (sl) 2013-10-30
CY1114377T1 (el) 2016-08-31
PT2475645E (pt) 2013-08-05
AR078352A1 (es) 2011-11-02
DK2475645T3 (da) 2013-07-22
SG179035A1 (en) 2012-04-27
ECSP12011723A (es) 2012-04-30
MX2012002254A (es) 2012-03-16
TWI412363B (zh) 2013-10-21
NZ597514A (en) 2013-10-25
MA33563B1 (fr) 2012-09-01
KR101382871B1 (ko) 2014-04-08
HRP20130869T1 (hr) 2013-10-25
WO2011029827A1 (en) 2011-03-17
BR112012005511B8 (pt) 2021-05-25
US8227491B2 (en) 2012-07-24
JP2013504534A (ja) 2013-02-07
JP5604520B2 (ja) 2014-10-08
IL217920A (en) 2015-11-30
US20110065759A1 (en) 2011-03-17
EP2475645B1 (en) 2013-07-03
HK1172021A1 (en) 2013-04-12
CL2012000611A1 (es) 2012-09-07
TW201114427A (en) 2011-05-01
UA107088C2 (xx) 2014-11-25
CN102639506B (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
MX2013002660A (es) Heteroarilmetilamidas.
PH12019502355A1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
IN2015DN01156A (fi)
IN2012DN01233A (fi)
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MD20140002A2 (ro) Indazoli
MX2011008171A (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
IN2014DN09434A (fi)
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
IN2012DN02081A (fi)
MX2014007057A (es) Triazolopiridinas sustituidas.
IN2012DN00971A (fi)
GB2511685A (en) Muscarinic m1 receptor agonists
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
IN2012DN00763A (fi)
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MY157429A (en) Trpm8 antagonists and their use in treatments
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare